Press release
Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market
Atypical hemolytic uremic syndrome market growth 2034
The [https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Atypical Hemolytic Uremic Syndrome market report also offers comprehensive insights into the Atypical Hemolytic Uremic Syndrome market size, share, Atypical Hemolytic Uremic Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Atypical Hemolytic Uremic Syndrome market size growth forward.
Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:
*
As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR
*
Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.
*
In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).
*
In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naive pediatric and adult patients with aHUS in China.
*
In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.
*
There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.
*
The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.
*
Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.
*
In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).
*
Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.
Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape [https://www.delveinsight.com/sample-request/atypical-hemolytic-uremic-syndrome-ahus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atypical Hemolytic Uremic Syndrome Overview
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare disorder marked by the destruction of red blood cells (causing hemolytic anemia), a reduced platelet count (thrombocytopenia), and acute kidney failure (uremia), which compromises the kidneys' ability to eliminate waste. In aHUS, red blood cells break apart as they move through clots in small blood vessels, and if the body can't produce new cells fast enough, anemia develops. This process can severely damage the kidneys, with about half of affected individuals progressing to end-stage renal disease (ESRD).
Diagnosing aHUS is often difficult, particularly in cases without a clear family history. It is primarily based on the combination of hemolytic anemia, low platelet levels, and signs of kidney impairment.
Treatment strategies focus on managing kidney injury and associated complications. Severe anemia may require transfusions of packed red blood cells, while platelet transfusions are reserved for extreme cases. Careful management of fluids and electrolytes is critical, nephrotoxic drugs should be avoided, and blood pressure must be controlled. In instances of kidney failure, renal replacement therapy may be needed. Targeted therapies such as plasma exchange and complement inhibitors, including eculizumab and ravulizumab, address the root cause of the disease.
Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report [https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atypical Hemolytic Uremic Syndrome Epidemiology Insights
*
DelveInsight's epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.
*
The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.
*
Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.
Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
DelveInsight's Atypical Hemolytic Uremic Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Atypical Hemolytic Uremic Syndrome historical patient pools and forecasted Atypical Hemolytic Uremic Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Atypical Hemolytic Uremic Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
*
Atypical Hemolytic Uremic Syndrome Prevalence
*
Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence
*
Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence
*
Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome
Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights [https://www.delveinsight.com/sample-request/atypical-hemolytic-uremic-syndrome-ahus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atypical Hemolytic Uremic Syndrome Market Insights:
*
Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
*
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
*
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
*
Among emerging therapies for aHUS, Novartis' iptacopan and Roche's crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.
Atypical Hemolytic Uremic Syndrome Market Outlook
The introduction of complement C5 inhibition has significantly enhanced patient outcomes and quality of life (QoL) in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). The available complement C5 inhibitors in the 7MM are SOLIRIS (eculizumab) and ULTOMIRIS (ravulizumab), both products of Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021.
Switching patients from eculizumab to ravulizumab has proven to be an effective treatment strategy. This transition reduces the frequency of dosing, resulting in lower treatment-related costs and improved patient QoL.
Despite their proven safety and effectiveness, the high cost of eculizumab and ravulizumab limits their accessibility in the treatment landscape. As a result, there is a significant need for more effective pharmacological options, especially for managing the more severe and disabling stages of aHUS.
While several promising therapies are under investigation for aHUS, it is too early to confirm which will enter the market during the forecast period (2024-2034). However, it is clear that the future of this market holds promise. These new treatments are expected to bring substantial improvements to the aHUS treatment landscape in the coming years, driven by increasing global healthcare spending.
Atypical Hemolytic Uremic Syndrome Marketed Drugs
*
ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals
*
SOLIRIS (eculizumab): Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome Emerging Drugs
*
Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical
*
FABHALTA (iptacopan): Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome Key Companies
*
Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others
Scope of the Atypical Hemolytic Uremic Syndrome Market Report [https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM
*
Atypical Hemolytic Uremic Syndrome marketed and emerging therapies
*
Atypical Hemolytic Uremic Syndrome companies
*
Atypical Hemolytic Uremic Syndrome market drivers and barriers
Table of Contents:
1 Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights
2 Atypical Hemolytic Uremic Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome
4 Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Atypical Hemolytic Uremic Syndrome
6 Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology
7 Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population
8 Atypical Hemolytic Uremic Syndrome Patient Journey
9 Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials
11 Atypical Hemolytic Uremic Syndrome Marketed Therapies
12 Atypical Hemolytic Uremic Syndrome Emerging Therapies
13 Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome
16 Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews
18 Atypical Hemolytic Uremic Syndrome Market Drivers
19 Atypical Hemolytic Uremic Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Atypical Hemolytic Uremic Syndrome Epidemiology 2034
DelveInsight's "Atypical Hemolytic Uremic Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Atypical Hemolytic Uremic Syndrome Pipeline 2024
"Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atypical Hemolytic Uremic Syndrome market. A detailed picture of the Atypical Hemolytic Uremic Syndrome pipeline landscape is provided, which includes the disease overview and Atypical Hemolytic Uremic Syndrome treatment guidelines.
Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected to Drive Market
The atypical hemolytic uremic syndrome market growth is driven by factors like increase in the prevalence of Atypical Hemolytic Uremic Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Atypical Hemolytic Uremic Syndrome market report also offers comprehensive insights into the Atypical Hemolytic Uremic Syndrome market size, share, Atypical Hemolytic Uremic Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Atypical Hemolytic Uremic Syndrome market size growth forward.
Some of the key highlights from the Atypical Hemolytic Uremic Syndrome Market Insights Report:
*
As per DelveInsight analysis, the Atypical Hemolytic Uremic Syndrome market is anticipated to witness growth at a considerable CAGR
*
Several key pharmaceutical companies, including Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others, are developing novel products to improve the Atypical Hemolytic Uremic Syndrome treatment outlook.
*
In April 2024, Hoffmann-La Roche revealed the results of a Phase III, multicenter, single-arm study assessing the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab in pediatric patients with atypical hemolytic uremic syndrome (aHUS).
*
In February 2024, Alexion Pharmaceuticals, Inc. announced the results of a prospective, single-arm, multicenter study evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in complement inhibitor treatment-naive pediatric and adult patients with aHUS in China.
*
In 2023, the United States had the largest market share for Atypical Hemolytic Uremic Syndrome (aHUS) among the 7MM, and this market is expected to grow with a compound annual growth rate (CAGR) of approximately 4% by 2034.
*
There are two types of HUS: Typical HUS, caused by pathogens like E. coli, and atypical HUS, which is often linked to genetic mutations, but can also be triggered by illnesses or other unknown causes. Most aHUS cases are genetic, although some can be acquired through autoantibodies or idiopathic causes. The condition can become chronic, leading to complications such as hypertension and kidney failure.
*
The disease is related to gene mutations and triggering events, like pregnancy, infections, cancers, and certain medications. The clinical manifestations of aHUS can involve various organ systems, including renal, hematologic, respiratory, ocular, skin, CNS, cardiovascular, and GI systems.
*
Diagnosis includes a complete blood count (CBC) to measure red blood cell and platelet counts, and an estimated glomerular filtration rate (eGFR) to assess kidney function.
*
In 2023, there were nearly 4,800 diagnosed cases of aHUS in the 7MM, with the majority of cases being in adults and adolescents (around 4,000 cases) compared to pediatric cases (approximately 700 cases).
*
Currently, only eculizumab and ravulizumab are approved for treatment, both developed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021. Iptacopan (LNP023), an oral drug by Novartis, is in Phase III trials and could become a preferred treatment due to its convenient oral administration. It is expected to generate over USD 500 million by 2034.
Strategise your business goals by understanding market dynamics @ Atypical Hemolytic Uremic Syndrome Market Landscape
Atypical Hemolytic Uremic Syndrome Overview
Atypical Hemolytic Uremic Syndrome (aHUS) is a rare disorder marked by the destruction of red blood cells (causing hemolytic anemia), a reduced platelet count (thrombocytopenia), and acute kidney failure (uremia), which compromises the kidneys' ability to eliminate waste. In aHUS, red blood cells break apart as they move through clots in small blood vessels, and if the body can't produce new cells fast enough, anemia develops. This process can severely damage the kidneys, with about half of affected individuals progressing to end-stage renal disease (ESRD).
Diagnosing aHUS is often difficult, particularly in cases without a clear family history. It is primarily based on the combination of hemolytic anemia, low platelet levels, and signs of kidney impairment.
Treatment strategies focus on managing kidney injury and associated complications. Severe anemia may require transfusions of packed red blood cells, while platelet transfusions are reserved for extreme cases. Careful management of fluids and electrolytes is critical, nephrotoxic drugs should be avoided, and blood pressure must be controlled. In instances of kidney failure, renal replacement therapy may be needed. Targeted therapies such as plasma exchange and complement inhibitors, including eculizumab and ravulizumab, address the root cause of the disease.
Do you know the treatment paradigms for different countries? Download our Atypical Hemolytic Uremic Syndrome Market Sample Report
Atypical Hemolytic Uremic Syndrome Epidemiology Insights
*
DelveInsight's epidemiology model estimates that there were approximately 5K diagnosed cases of aHUS across the 7MM in 2023, with this number expected to rise throughout the forecast period.
*
The United States had the highest number of aHUS cases, with nearly 3,500 cases reported in 2023, and this figure is projected to increase by 2034.
*
Among the 7MM, adolescents and adults made up about 80% of the diagnosed cases in 2023.
Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation
DelveInsight's Atypical Hemolytic Uremic Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Atypical Hemolytic Uremic Syndrome historical patient pools and forecasted Atypical Hemolytic Uremic Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Atypical Hemolytic Uremic Syndrome Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
*
Atypical Hemolytic Uremic Syndrome Prevalence
*
Age-Specific Atypical Hemolytic Uremic Syndrome Prevalence
*
Gender-Specific Atypical Hemolytic Uremic Syndrome Prevalence
*
Diagnosed and Treatable Cases of Atypical Hemolytic Uremic Syndrome
Visit for more @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights
Atypical Hemolytic Uremic Syndrome Market Insights:
*
Several major companies, including Alexion Pharmaceuticals, Novartis, and Roche, are leading the Atypical Hemolytic Uremic Syndrome (aHUS) treatment landscape. The market details, broken down by country and therapy, are outlined below.
*
According to DelveInsight's patient-based forecasting model, the total aHUS market size in the 7MM was USD 1.3 billion in 2023, and significant growth is anticipated during the forecast period due to the introduction of new therapies.
*
In 2023, the United States accounted for the largest share of the aHUS market in the 7MM, approximately 70%, followed by Germany and France.
*
Among emerging therapies for aHUS, Novartis' iptacopan and Roche's crovalimab are expected to play a pivotal role in transforming the market. By 2034, iptacopan is projected to generate the highest revenue among emerging treatments, with nearly USD 100 million expected in the EU4 and the UK.
Atypical Hemolytic Uremic Syndrome Market Outlook
The introduction of complement C5 inhibition has significantly enhanced patient outcomes and quality of life (QoL) in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). The available complement C5 inhibitors in the 7MM are SOLIRIS (eculizumab) and ULTOMIRIS (ravulizumab), both products of Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2021.
Switching patients from eculizumab to ravulizumab has proven to be an effective treatment strategy. This transition reduces the frequency of dosing, resulting in lower treatment-related costs and improved patient QoL.
Despite their proven safety and effectiveness, the high cost of eculizumab and ravulizumab limits their accessibility in the treatment landscape. As a result, there is a significant need for more effective pharmacological options, especially for managing the more severe and disabling stages of aHUS.
While several promising therapies are under investigation for aHUS, it is too early to confirm which will enter the market during the forecast period (2024-2034). However, it is clear that the future of this market holds promise. These new treatments are expected to bring substantial improvements to the aHUS treatment landscape in the coming years, driven by increasing global healthcare spending.
Atypical Hemolytic Uremic Syndrome Marketed Drugs
*
ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals
*
SOLIRIS (eculizumab): Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome Emerging Drugs
*
Crovalimab (RG6107; SKY59): Hoffmann-La Roche/Chugai Pharmaceutical
*
FABHALTA (iptacopan): Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome Key Companies
*
Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, and others
For more information, visit Atypical Hemolytic Uremic Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Atypical Hemolytic Uremic Syndrome Market Report:
*
11 Years Forecast
*
7MM Coverage
*
Descriptive overview of Atypical Hemolytic Uremic Syndrome, causes, signs and symptoms, diagnosis, treatment
*
Comprehensive insight into Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM
*
Atypical Hemolytic Uremic Syndrome marketed and emerging therapies
*
Atypical Hemolytic Uremic Syndrome companies
*
Atypical Hemolytic Uremic Syndrome market drivers and barriers
Table of Contents:
1Atypical Hemolytic Uremic Syndrome Market Key Comprehensive Insights
2Atypical Hemolytic Uremic Syndrome Market Report Introduction
3Competitive Intelligence Analysis for Atypical Hemolytic Uremic Syndrome
4Atypical Hemolytic Uremic Syndrome Market Analysis Overview at a Glance
5Executive Summary of Atypical Hemolytic Uremic Syndrome
6Atypical Hemolytic Uremic Syndrome Epidemiology and Market Methodology
7Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population
8Atypical Hemolytic Uremic Syndrome Patient Journey
9Atypical Hemolytic Uremic Syndrome Treatment Algorithm, Atypical Hemolytic Uremic Syndrome Current Treatment, and Medical Practices
10Key Endpoints in Atypical Hemolytic Uremic Syndrome Clinical Trials
11Atypical Hemolytic Uremic Syndrome Marketed Therapies
12Atypical Hemolytic Uremic Syndrome Emerging Therapies
13Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis
14Attribute analysis
15Access and Reimbursement Overview of Atypical Hemolytic Uremic Syndrome
16Atypical Hemolytic Uremic Syndrome Market Key Opinion Leaders Reviews
18Atypical Hemolytic Uremic Syndrome Market Drivers
19Atypical Hemolytic Uremic Syndrome Market Barriers
20SWOT Analysis
21Disclaimer
22DelveInsight Capabilities
23About DelveInsight
Related Reports:
Atypical Hemolytic Uremic Syndrome Epidemiology 2034
DelveInsight's "Atypical Hemolytic Uremic Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Atypical Hemolytic Uremic Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Atypical Hemolytic Uremic Syndrome Pipeline 2024
"Atypical Hemolytic Uremic Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Atypical Hemolytic Uremic Syndrome market. A detailed picture of the Atypical Hemolytic Uremic Syndrome pipeline landscape is provided, which includes the disease overview and Atypical Hemolytic Uremic Syndrome treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atypical-hemolytic-uremic-syndrome-market-expected-rise-2034-alexion-pharmaceuticals-omeros-corporation-novartis-pharmaceuticals-hoffmannla-roche-chugai-pharmaceutical-expected-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market here
News-ID: 3989334 • Views: …
More Releases from ABNewswire
Fuchs Endothelial Corneal Dystrophy Market Poised for Robust Growth by 2034 | De …
The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing disease awareness, improved diagnostic capabilities, and substantial investments in research by key Fuchs Dystrophy companies, such as Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, and Presbia, among others.
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insight,…
Dermatoscope Market Projected to Reach USD 2 Billion by 2030, Growing at a CAGR …
The global dermatoscope market is experiencing robust growth, driven by several factors. Key dermatoscope manufacturers include Canfield Scientific, Inc., FotoFinder Systems GmbH, DermLite, Firefly Global, Caliber Imaging and Diagnosis, Optilia Medical, Baxter, Bio-Therapeutic, HEINE Optotechnik GmbH & Co. KG, ILLUCO, Courage+Khazaka electronic GmbH, Rudolf Riester GmbH, AnMo Electronics Corporation, NIDEK CO., LTD., and KIRCHNER & WILHELM GmbH + Co. KG, among others.
DelveInsight's "Dermatoscope Market Insight, Competitive Landscape and Market Forecast…
Chronic Kidney Disease Market Poised for Rapid Growth Amid FDA Drug Approvals | …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others.
DelveInsight's "Chronic Kidney Disease Market Insight, Epidemiology,…
Bullous Keratopathy Market Poised for Robust Growth at an 11.5% CAGR Over the Co …
The bullous keratopathy treatment market is projected to experience substantial growth over the coming decade, driven by an aging population, increasing prevalence of cataract surgeries, glaucoma procedures, and novel pharmaceutical interventions by key bullous keratopathy players such as Aurion Biotechnologies, Emmecell, Trefoil Therapeutics, and Cellusion, among others.
DelveInsight's "Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/bullous-keratopathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of bullous keratopathy, historical and forecasted epidemiology,…
More Releases for Atypical
Atypical Antipsychotic Drugs Market Size, Share, Emerging Trends, Analysis and F …
The latest Antipsychotic Drugs Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Antipsychotic Drugs Market.
Psychosis…
Atypical Antipsychotic Drugs Market Size, Share, Development by 2025
Market Research Report Store offers a latest published report on Atypical Antipsychotic Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. They do not cure psychosis but help in controlling symptoms such as hallucinations, and delusions, among others.
The global Atypical Antipsychotic Drugs market is valued at…
Atypical Antipsychotic Drugs Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Atypical Antipsychotic Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Atypical Antipsychotic Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
Recent Study Explores ATYPICAL HEMOLYTIC UREMIC SYNDROME Industry Pipeline Revie …
Overview
Latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) pipeline landscape.
Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the…
Global Atypical Chemokine Receptor 3 Market Trend, Analysis, Top-Manufacturers & …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Atypical Chemokine Receptor 3 Market Research Report 2018” which provides an outlook of current market growth as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR near XX% during 2018-2025. The report studies the atypical chemokine receptor 3 market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and…
Atypical Chemokine Receptor 3 Market Pipeline Review, H2 2017
"The Report Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
According to the recently published report Atypical Chemokine Receptor-Pipeline Review, H2 2017; Atypical Chemokine Receptor 3…
